Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Recent advances in the development of dopamine D3 receptor antagonists: a medicinal chemistry perspective.

Micheli F.

ChemMedChem. 2011 Jul 4;6(7):1152-62. doi: 10.1002/cmdc.201000538. Epub 2011 Mar 18. Review.

PMID:
21425240
2.

Selective dopamine D3 receptor antagonists: a review 2001-2005.

Micheli F, Heidbreder C.

Recent Pat CNS Drug Discov. 2006 Nov;1(3):271-88. Review.

PMID:
18221209
3.

Exploration of the amine terminus in a novel series of 1,2,4-triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists.

Micheli F, Arista L, Bertani B, Braggio S, Capelli AM, Cremonesi S, Di-Fabio R, Gelardi G, Gentile G, Marchioro C, Pasquarello A, Provera S, Tedesco G, Tarsi L, Terreni S, Worby A, Heidbreder C.

J Med Chem. 2010 Oct 14;53(19):7129-39. doi: 10.1021/jm100832d.

PMID:
20839775
4.
5.
6.

Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.

Campiani G, Butini S, Trotta F, Fattorusso C, Catalanotti B, Aiello F, Gemma S, Nacci V, Novellino E, Stark JA, Cagnotto A, Fumagalli E, Carnovali F, Cervo L, Mennini T.

J Med Chem. 2003 Aug 28;46(18):3822-39.

PMID:
12930145
7.

Dopamine D3 receptor antagonists as therapeutic agents.

Joyce JN, Millan MJ.

Drug Discov Today. 2005 Jul 1;10(13):917-25. Review.

PMID:
15993811
8.

[3-azabicyclo[3.1.0]hex-1-yl]phenyl-benzenesulfonamides as selective dopamine D3 antagonists.

Micheli F, Hamprecht D, Bonanomi G, Di Fabio R, Donati D, Gentile G, Heidbreder C, Prandi A, Tarsi L, Terreni S.

Bioorg Med Chem Lett. 2010 Sep 15;20(18):5491-4. doi: 10.1016/j.bmcl.2010.07.073. Epub 2010 Jul 21.

PMID:
20692836
9.

Dopamine D(3) receptor antagonists: The quest for a potentially selective PET ligand. Part two: Lead optimization.

Micheli F, Holmes I, Arista L, Bonanomi G, Braggio S, Cardullo F, Di Fabio R, Donati D, Gentile G, Hamprecht D, Terreni S, Heidbreder C, Savoia C, Griffante C, Worby A.

Bioorg Med Chem Lett. 2009 Aug 1;19(15):4011-3. doi: 10.1016/j.bmcl.2009.06.028. Epub 2009 Jun 13.

PMID:
19553113
10.

Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.

Heidbreder CA, Newman AH.

Ann N Y Acad Sci. 2010 Feb;1187:4-34. doi: 10.1111/j.1749-6632.2009.05149.x. Review.

11.

1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists.

Micheli F, Arista L, Bonanomi G, Blaney FE, Braggio S, Capelli AM, Checchia A, Damiani F, Di-Fabio R, Fontana S, Gentile G, Griffante C, Hamprecht D, Marchioro C, Mugnaini M, Piner J, Ratti E, Tedesco G, Tarsi L, Terreni S, Worby A, Ashby CR Jr, Heidbreder C.

J Med Chem. 2010 Jan 14;53(1):374-91. doi: 10.1021/jm901319p.

PMID:
19891474
12.

Dopamine D3 and D4 receptor antagonists in the treatment of schizophrenia.

Jardemark K, Wadenberg ML, Grillner P, Svensson TH.

Curr Opin Investig Drugs. 2002 Jan;3(1):101-5. Review.

PMID:
12054059
13.

Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.

Visanji NP, Fox SH, Johnston T, Reyes G, Millan MJ, Brotchie JM.

Neurobiol Dis. 2009 Aug;35(2):184-92. doi: 10.1016/j.nbd.2008.11.010. Epub 2008 Dec 9.

PMID:
19118628
14.

Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse.

Mason CW, Hassan HE, Kim KP, Cao J, Eddington ND, Newman AH, Voulalas PJ.

J Pharmacol Exp Ther. 2010 Jun;333(3):854-64. doi: 10.1124/jpet.109.165084. Epub 2010 Mar 12.

15.

Recent advances in the development of dopamine D(3) receptor agonists and antagonists.

Crider AM, Scheideler MA.

Mini Rev Med Chem. 2001 May;1(1):89-99. Review.

PMID:
12369994
16.

Dopamine D3 receptor antagonists: a patent review (2007 - 2012).

Micheli F, Heidbreder C.

Expert Opin Ther Pat. 2013 Mar;23(3):363-81. doi: 10.1517/13543776.2013.757593. Epub 2013 Jan 3. Review.

PMID:
23282131
17.

KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.

Park WK, Jeong D, Cho H, Lee SJ, Cha MY, Pae AN, Choi KI, Koh HY, Kong JY.

Pharmacol Biochem Behav. 2005 Oct;82(2):361-72. Epub 2005 Oct 10.

PMID:
16216322
18.

Synthesis and SAR of highly potent and selective dopamine D3-receptor antagonists: variations on the 1H-pyrimidin-2-one theme.

Geneste H, Amberg W, Backfisch G, Beyerbach A, Braje WM, Delzer J, Haupt A, Hutchins CW, King LL, Sauer DR, Unger L, Wernet W.

Bioorg Med Chem Lett. 2006 Apr 1;16(7):1934-7. Epub 2006 Jan 24.

PMID:
16439127
19.

New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.

Micheli F, Bonanomi G, Braggio S, Capelli AM, Celestini P, Damiani F, Di Fabio R, Donati D, Gagliardi S, Gentile G, Hamprecht D, Petrone M, Radaelli S, Tedesco G, Terreni S, Worby A, Heidbreder C.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):901-7. doi: 10.1016/j.bmcl.2007.12.066. Epub 2008 Jan 3.

PMID:
18248991
20.

Dopamine D3 receptor ligands with antagonist properties.

Hackling AE, Stark H.

Chembiochem. 2002 Oct 4;3(10):946-61. Review.

PMID:
12362359

Supplemental Content

Support Center